1 / 34

Actinomycin-D / Vincristine in Pediatric Oncology Trials: COG Effort

Actinomycin-D / Vincristine in Pediatric Oncology Trials: COG Effort. Jeffrey S. Barrett, Ph.D., FCP The Children’s Hospital of Philadelphia Division of Clinical Pharmacology and Therapeutics The University of Pennsylvania Medical School Department of Pediatrics. Outline. Introduction

adina
Download Presentation

Actinomycin-D / Vincristine in Pediatric Oncology Trials: COG Effort

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Actinomycin-D / Vincristine in Pediatric Oncology Trials: COG Effort Jeffrey S. Barrett, Ph.D., FCPThe Children’s Hospital of PhiladelphiaDivision of Clinical Pharmacology and TherapeuticsThe University of Pennsylvania Medical SchoolDepartment of Pediatrics

  2. Outline • Introduction • Clinical Setting for AMD / VCR in Pediatric Oncology • “Missing” Data and the Impact on Pharmacotherapy • Grant Overview • Objectives and Goals • Project Descriptions • Current Status • Project Plan Update • Overall Milestones Achieved to Date • By Project Review • Critical Activities • Next Steps

  3. Introduction • In August of 2002, the Children’s Oncology Group (COG) suspended 3 active protocols for pediatric rhabdomyosarcoma after 4 chemotherapy-associated deaths from VOD. • No subsequent evaluation as to the cause of these devastating side effects or correlation between toxicity and drug exposure. • Primarily by the limited pharmacokinetic knowledge of AMD. • Because AMD is crucial to soft tissue sarcoma therapy, its use as an anti-neoplastic agent continues; clinical evaluation vital.

  4. Introduction • June 24, 2004: NIH requests that the COG responds to an RFP focused on enhancing the safety and effectiveness of AMD and VCR administered to children with cancer. • July 21, 2004: COG provide LOI with 4 project proposals • August 11, 2004: Full proposal submitted to NIH / NCI • October 1, 2004: Award made to COG • March 31, 2005: Results of initial M&S activities presented to NIH/NCI at COG meeting – initial requirements gathered for Simulation Plan • October 20, 2005: Update on grant progress to FDA Pediatric Oncology Subcommittee

  5. Study Sub study Study Dates Pediatric Indications N Treatment groups Duration VA, VAD ± XRT, NWTS-4 NA 1986-1989 2382 VA, VAD 24 to 66 wk VECD ± XRT NWTS-5 Relapse study 1995-2002 Wilms’ tumor - relapsed patients 203 VA ± XRT, VAD ± XRT 18 or 24 wk Biology study 1995-2002 Wilms’ tumor, kidney sarcoma, kidney rhabdoid 18 or 24 wk IRS-4 NA 1991-1997 RMS 883 VA, VAC, VAI, VIE 1 y except VA, 36wk IRS-5 D9602 1997-2004 Low risk RMS 367 VA ± XRT, VAC ± XRT 47 wk D9803 1999 - Intermediate risk RMS 518 VAC ± XRT , V/TOPO/C+XRT 39 wk IntroductionClinical Setting – Historical experience in children

  6. IntroductionClinical Setting – Historical experience in children

  7. IntroductionImpact of “Missing” Data on Pharmacotherapy • No analytical methodology for AMD • PK largely unknown – No idea about dose-exposure. • PD largely unknown. • AMD Dose-toxicity relationship qualitative at best • VCR PK not well defined in pediatric populations • Exposure-response (toxicity) not well defined. • PGx component to PK and/or clinical outcomes suspected but not defined. • Dose-limiting vs manageable toxicity unclear • Dose adjustments empirically based • No basis for age / size modification • No basis for special populations (e.g., renal impairment) • No guidance on drug interactions

  8. Grant OverviewObjectives and Goals Project 1: To conduct a retrospective analysis of historical data from Wilms tumor (NWTS-IV and NWTS-V) and rhabdomyosarcoma (IRS-IV and IRS-V) studies in which vincristine and actinomycin-D were administered to various pediatric subpopulations in order to define exposure-toxicity relationships. Project 2: To develop a dosing and pharmacokinetic sampling procedure for actinomycin and vincristine utilizing a single lumen central venous catheter. Project 3: To construct PK/PD models based on actinomycin-D and vincristine exposure-response relationships that incorporate physiologic-based and mechanistic expression when possible, and simulation to extend such relationships into a clinical trial paradigm in which trial outcomes may be predicted. Project 4: To conduct a prospective PK/PD/outcome trial of vincristine and actinomycin-D in children, primarily less than 3 years of age, receiving these drugs as a component of their therapy.

  9. Grant OverviewInterdependencies Overall success highly dependent on project management and communication

  10. Grant OverviewProject Descriptions – Project 1 Aim 1: To describe vincristine and actinomycin D dosing for patients on NWTSG 4 and 5 and IRSG IV and V Aim 2: Correlate dosing data from Aim 1 with efficacy, particularly in children less than 3 years of age Aim 3: Correlate dosing data from Aim 1 with toxicity, particularly in children less than 3 years of age Aim 4: Analyze the combined NWTSG and IRSG datasets with classification and regression tree methodology to provide background data for the clinical trial simulation described in Project 3

  11. Study Design and Analytic Methods Trial Design Data and Analysis Plan Aim 1 Aim 2 Aim 3 Aim 4 NTWS 4 Case cohort Individual dose description and analysis Standard univariate and multivariate analyses Standard univariate and multivariate analyses Classification and regression tree models on combined data set NTWS 5 IRS 4 Cohort Course dose description and analysis IRS 5 Cohort Individual dose description and analysis Grant OverviewProject Descriptions – Project 1

  12. Grant OverviewProject Descriptions – Project 2 Aim 1: To examine the recovery of actinomycin-D and vincristine in common catheter configurations which would be utilized to administered these agents via a central venous line. Aim 2: To assess the in vitro equivalence of catheter configurations utilized for sampling purposes Aim 3: To develop procedures for dosing and sampling to ensure robust sampling equivalent to a separate sampling line Aim 4: To validate the procedure proposed in Aim 3 via clinical testing to the target patient population (children with cancer)

  13. Grant OverviewProject Descriptions – Project 2 Develop and validate a single LC/MS/MS assay to quantify both Act-D and VCR Determine cytochrome P450s involved in the metabolism of Act-D Optimize plasma sampling techniques for PK studies in children Create a pilot PK study of Act-D and VCR in children

  14. Grant OverviewProject Descriptions – Project 3 Aim 1: Develop PBPK models for actinomycin and vincristine from historical pharmacokinetic data for the prediction of plasma pharmacokinetics and exposure in organs and tissues. Aim 2: Incorporate dose/toxicity data from the historical literature and Project 1 into the PBPK models to associate specific organ exposures to toxicity outcomes. Aim 3: Conduct a pilot study in pediatric patients using extensive plasma sampling to further define AMD and VCR pharmacokinetics and inter-subject variability for model refinement. Aim 4: Perform Clinical Trial Simulations for the design of the prospective PK/PD trial proposed in Project 4.

  15. Grant OverviewProject Descriptions – Project 3 Dose – Exposure Relationships Exposure – Response Relationships Data Sources • PBPK Model in the Dog • Define in NONMEM • Add precision estimate • Dose – AE Model • Pooled from Literature • Define response profile • Literature Priors • Animal and human PK • Variance in physiology • Scaling principals • In vitro binding data • Cellular partitioning • Clinical trial summaries (AE/SAE) • PBPK Model in the Adult • Scale Dog to Human • QC plasma exposure • Mechanistic PK/PD Model • Map transduction process • Biophase concentration • Correlate with in vitro data • PBPK Model in the Child • Scale CL allometrically • QC plasma exposure Individual AE Data (COG) • • Clinical Response Model • AE vs Pred. Exposure(dose) • Add variance components • Add covariate structure • Pilot PK Study • Dose Finding Trial • PBPK Pediatric Pop Model • Add variance components • Add covariate structure Dosing Guidance for Pediatric Cancer Patients

  16. Grant OverviewProject Descriptions – Project 4 Aim 1: Develop and finalize a clinical protocol based on the observed toxicity-dose response (Project 1) and the clinical trial simulation results (Project 3) utilizing a single lumen catheter procedure defined by Project 2. Aim 2: Evaluate AMD/VCR dose-exposure relationships via nonlinear mixed effect modeling incorporating covariates that explain sources of variation including size, age, heritable and non-heritable sources. Aim 3: Create PK/PD models (based on Aim 2) that correlate toxicity findings and clinical outcomes from the prospective trial CTS results and catheter experiment results (procedures defined by Project 2) Aim 4: Propose dosing guidance for actinomycin-D and vincristine based on clinical utility (maximizing therapeutic outcome and minimizing therapeutic risk) suitable for label recommendations

  17. Current StatusProject Plan

  18. Current StatusMilestones Achieved • Analytical method for AMD/VCR quantification in pediatric plasma samples validated and published • Procedure for AMD/VCR dosing/sampling from central catheter has been developed (awaiting clinical validation) • Pilot PK study initiated; 3 (8 planned) enrolled • PBPK models for AMD and VCR developed and scaled to project pediatric exposures • PK models refined for CTS application • CTS Plan completed; CTS ongoing • Draft clinical protocol circulated to NIH and select COG phase 1 sites

  19. Current StatusBy Project Review – Project 1 • NWTS database created • Data errors and inconsistencies continue to be an issue and are being resolved • Data entry of non-electronically available data delayed • SAP finalized

  20. Current StatusBy Project Review – Project 2 AMD/VCR method validated, published and continues refinement (with LOD < 0.1 ng/mL probable)

  21. Current StatusBy Project Review – Project 2 AMD/VCR method validated, published and continues refinement (with LOD < 0.1 ng/mL probable)

  22. Current StatusBy Project Review – Project 2 In vivo performance of analytical method already demonstrated in pilot study patients

  23. Current StatusBy Project Review – Project 2 Clinical procedure and apparatus for dosing / sampling from a central venous catheter developed Flush Volume: 1. Cook® 5 french 27cm catheter fragment 2. 200 µL pipette tip 3. Cook® catheter connector 4. Medex® 3-way stopcock 5. 3 mL syringe for sample collection 6. 5 mL syringe for waste collection

  24. Current StatusBy Project Review – Project 3 PBPK Models developed for AMD and VCR – Scaled to pediatric populations PLASMA FLOW • Model Elements – AMD and VCR • Flow-limited PBPK models derived from dog • Human physiologic parameters inserted and rescaled allometrically for pediatric subjects • Moderate variation in physiologic and PK processes assumed to date • Models expressed in NONMEM and TS2 • Initial simulations agree with historical data in children based on plasma exposure PLASMA HEART HEPATIC ARTERY SPLEEN LIVER BILE KIDNEY URINE BONE MARROW MUSCLE CARCASS

  25. Current StatusBy Project Review – Project 3 • Good agreement with Veal et. al. (n=31) and CHOP pilot PK study (n=2)

  26. Current StatusBy Project Review – Project 3 Models refined based on pediatric data obtained from UKCCSG (Veal et. al.) • Model developed using the First-Order Conditional Estimation method in NONMEM • 165 plasma concentrations collected from 33 pediatric patients administered 0.70 to 1.50 mg/m2 AMD • A three-compartment model with first-order elimination was chosen as the structural model • Random effects to describe the inter-subject variability were included for V1 and CL

  27. Current StatusBy Project Review – Project 3 Simulation plan completed (available for review) • Simulation Scenarios: • Previous IRS and NWTS Trials • Dosing Modifications in Infants • BSA vs BW Dosing • Dose Capping • Clinical Study Designs and Sampling Considerations • Adverse Event Rates for Prospective Study • Clinical response for Prospective Study

  28. Current StatusBy Project Review – Project 3 Uncertainty in Var CL Novelty of M&S Approach Uncertainty in Mean CL Residual Variability Interindividual Variability: CL Ct = D/V*e-CLi/V*t + et

  29. Current StatusBy Project Review – Project 3 Novelty of M&S Approach • Clinical Reality • Discrepancy across studies • Population, dosing, treatment diversity exists as well as compliance with targeted regimens / exposures • Correlation with toxicity difficult to assess from conventional analyses • Guidance for prospective study based on historical data difficult • Pharmacometric Solution • Global sensitivity analysis • Plot the MPE and RMSE against the population means (with uncertainty) for each simulation scenario • Identify study designs that produce minimal bias and high precision over the range of possible parameters

  30. Current StatusBy Project Review – Project 4 Clinical Protocol Draft Circulated PROSPECTIVE PHARMACOKINETIC/PHARMACODYNAMIC AND OUTCOME TRIAL OF ACTINOMYCIN-D AND VINCRISTINE IN CHILDREN WITH CANCER

  31. Critical Activities • Completion of pilot PK study and in vivo validation of central venous catheter dosing/sampling procedure • Completion of data entry / assembly for historical AE/tox data from IRS and MWTS trials • Correlation of tox with dosing metrics • Completion of key CTS scenarios

  32. Critical Activities • Revision and finalization of clinical protocol • Investigator solicitation and education • Data collection strategy, data management plan for prospective trial • SAP for prospective study • Label exercise based on CTS output

  33. References Barrett JS, Skolnik J, Gastonguay MR and Adamson PC. The Value of Priors and Prior Uncertainty in Clinical Trial Simulation: Case Study with Actinomycin-D in Children with Cancer. Presented, 2004 Population Approach Group Europe Meeting, Uppsala, Sweden, June 17-19, 2004. Skolnik J, Barrett JS, Shi H, and Adamson PC. Pre-clinical Studies in Support of the Clinical Pharmacologic Evaluation of Actinomycin-D in Children with Cancer. American College of Clinical Pharmacology Meeting, Phoenix, AZ, October 3-5, 2004. Mondick J and Barrett JS. A Physiologically-based Pharmacokinetic Model to Predict Tissue Distribution of Actinomycin-D in Humans. American College of Clinical Pharmacology Meeting, Phoenix, AZ, October 3-5, 2004. Skolnik JM, Paccaly DA, Barrett JS, Adamson PC. Mechanisms to enhance enrollment in pediatric trials: An in vitro procedure to clear residual chemotherapeutics from indwelling catheters. J. Clin. Pharmacol 2005; 45: 1085 (Abstr. 76). Barrett JS, Mondick JT, Skolnik J, Adamson PC. Clinical trial simulation in an academic research setting: Engaging the clinical team and generating the simulation plan. J. Clin. Pharmacol 2005; 45: 1087 (Abstr. 85). Skolnik, JM, Barrett, JS, Hsi, H, Adamson, PC; A liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of actinomycin-D and vincristine in children with cancer. Cancer Chemotherapy and Pharmacology; Sep 27;:1-7 [Epub ahead of print]

More Related